AGO2 and prostate carcinoma: Confirmation of AGO2 expression with miR-17-5p and miR-17-5p-targeted mRNA was performed with hepatocellular carcinoma cell lines HepG2 and JHH-1, breast cancer cell lines MDA-MB-231, prostate cancer cell lines DU145 and PC3, and lung cancer cell line A549 (Figure 5a).